The Use of Azelastine Hydrochloride/Fluticasone Propionate in the Management of Allergic Rhinitis in Asia: A Review

References

• Bunnag C, Jareoncharsri P, Tantilipikorn P, Vichyanond P, Pawankar R. Epidemiology and current status of allergic rhinitis and asthma in Thailand -ARIA Asia-Pacific Workshop report. Asian Pac J Allergy Immunol. 2009;27(1):79–86.
   PubMed Web of Science ®Google Scholar
• Jaruvongvanich V, Mongkolpathumrat P, Chantaphakul H, Klaewsongkram J. Extranasal symptoms of allergic rhinitis are difficult to treat and affect quality of life. Allergol Int. 2016;65(2):199–203. doi:10.1016/j.alit.2015.11.006
   PubMed Web of Science ®Google Scholar
• Mösges R, Lee DL, Abong J, et al. Role of bilastine in the management of allergic rhinitis and urticaria: an Asia-Pacific consensus statement. Asia Pacific Aller. 2016;6(1):56–66. doi:10.5415/apallergy.2016.6.1.56
   PubMed Web of Science ®Google Scholar
• Bunupuradah T, Siriaksorn S, Hinds D, Shantakumar S, Mulgirigama A, Aggarwal B. A survey of management practices in coexistent allergic rhinitis and asthma (Asia-pacific Survey of Physicians on Asthma and Allergic Rhinitis): results from Thailand. Asia Pacific Aller. 2019;31:9.
   Google Scholar
• Berger WE, Mustakov TB, Kralimarkova TZ, Christoff G, Popov TA. Treatment with azelastine hydrochloride and fluticasone propionate in a single delivery device of young children and adolescents with allergic rhinitis. Allergy Asthma Proc. 2020;41(4):232–239. doi:10.2500/aap.2020.41.200034
   PubMed Web of Science ®Google Scholar
• Pawankar R White Book on Allergy: update 2013. Available from: http://www.worldallergy.org/UserFiles/file/WhiteBook2-2013-v8.pdf. Accessed June 1, 2024.
   Google Scholar
• Brożek JL, Bousquet J, Agache I, Agarwal A, Bachert C. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision. J Allergy Clin Immunol. 2017;140(4):950–958. doi:10.1016/j.jaci.2017.03.050
   PubMed Web of Science ®Google Scholar
• Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ. Allergic rhinitis and its impact on asthma (ARIA) 2008. Allergy. 2008;63:8–160. doi:10.1111/j.1398-9995.2007.01620.x
   PubMed Web of Science ®Google Scholar
• Thanaviratananich S, Cho SH, Ghoshal AG, et al. Burden of respiratory disease in Thailand: results from the APBORD observational study. Medicine (Baltimore). 2016;95(28):e4090. doi:10.1097/MD.0000000000004090
   PubMed Web of Science ®Google Scholar
• Bachert C, Bousquet J, Hellings P. Rapid onset of action and reduced nasal hyperreactivity: new targets in allergic rhinitis management. Clin Transl Allergy. 2018;8(1):25. doi:10.1186/s13601-018-0210-2
   PubMedGoogle Scholar
• Harrow B, Sedaghat AR, Caldwell-Tarr A, Dufour R. A comparison of health care resource utilization and costs for patients with allergic rhinitis on single-product or free-combination therapy of intranasal steroids and intranasal antihistamines. J Manag Care Special Pharm. 2016;12:1426–1436. doi:10.18553/jmcp.2016.22.12.1426
   Google Scholar
• Meltzer EO, LaForce C, Ratner P, Price D, Ginsberg D, Carr W. MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial of efficacy and safety. Allergy Asthma Proc. 2012;33(4):324–332. doi:10.2500/aap.2012.33.3587
   PubMed Web of Science ®Google Scholar
• Kulthanan K, Chusakul S, Recto MT, Gabriel M, Aw DC. Economic burden of the inadequate management of allergic rhinitis and urticaria in asian countries based on the GA2LEN model. Allergy Asthma Immunol Res. 2018;10(4):370–378. doi:10.4168/aair.2018.10.4.370
   PubMed Web of Science ®Google Scholar
• Varshney J, Varshney H. Allergic rhinitis: an overview. Indian J Otolaryngol Head Neck Surg. 2015;67(2):143–149. doi:10.1007/s12070-015-0828-5
   PubMedGoogle Scholar
• May JR, Dolen WK. Management of allergic rhinitis: a review for the community pharmacist. Clin. Ther. 2017;39(12):2410–2419. doi:10.1016/j.clinthera.2017.10.006
   PubMed Web of Science ®Google Scholar
• Marple BF, Fornadley JA, Patel AA, et al.; American Academy of Otolaryngic Allergy Working Group on Allergic Rhinitis. Keys to successful management of patients with allergic rhinitis: focus on patient confidence, compliance, and satisfaction. Otolaryngol-Head Neck Surg. 2007;136(S6):S107–24. doi:10.1016/j.otohns.2007.02.031
   PubMedGoogle Scholar
• The diagnosis and management of rhinitis: an updated practice parameter - journal of allergy and clinical immunology. Available from: https://www.jacionline.org/article/S0091-6749(08)01123-8/fulltext. Accessed March 17, 2023.
   Google Scholar
• Rhinitis: a practical and comprehensive approach - Google scholar. Available from: https://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2007&pages=S5-S27&journal=J+Otolaryngol&issue=%00null%00&issn=%00empty%00&author=Small+P.&author=Frenkiel+S.&author=Becker+A.&title=Rhinitis%3A+A+practical+and+comprehensive+appro. Accessed March 17, 2023.
   Google Scholar
• Carr WW, Ratner P, Munzel U, Murray R, Price D. Comparison of intranasal azelastine to intranasal fluticasone propionate for symptom control in moderate-to-severe seasonal allergic rhinitis. Allergy Asthma Proc. 2012;33(6):450–458. doi:10.2500/aap.2012.33.3626
   PubMed Web of Science ®Google Scholar
• Derendorf H, Munzel U, Petzold U, Maus J, Mascher H. Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29‐02, a novel aqueous nasal spray. Br. J. Clin. Pharmacol. 2012;74(1):125–133. doi:10.1111/j.1365-2125.2012.04222.x
   PubMed Web of Science ®Google Scholar
• Hampel FC, Ratner PH, Van Bavel J, Amar NJ, Daftary P. Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device. Ann Allergy Asthma Immunol. 2010;10(2):168–173. doi:10.1016/j.anai.2010.06.008
   Google Scholar
• Meltzer E, Ratner P, Bachert C, et al. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. Int Arch Allergy Immunol. 2013;161(4):369–377. doi:10.1159/000351404
   PubMed Web of Science ®Google Scholar
• Carr W, Bernstein J, Lieberman P, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol. 2012;129(5):1282–1289. doi:10.1016/j.jaci.2012.01.077
   PubMed Web of Science ®Google Scholar
• Berger WE, Shah S, Lieberman P, et al. Long-term, randomized safety study of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) in subjects with chronic rhinitis. J Allergy Clin Immunol Pract. 2014;2(2):179–185. doi:10.1016/j.jaip.2013.09.019
   PubMed Web of Science ®Google Scholar
• Berger W, Meltzer EO, Amar N, et al. Efficacy of MP-AzeFlu in children with seasonal allergic rhinitis: importance of paediatric symptom assessment. Pediatr Allergy Immunol. 2016;27(2):126–133. doi:10.1111/pai.12540
   PubMed Web of Science ®Google Scholar
• Berger W, Bousquet J, Fox AT, et al. MP-AzeFlu is more effective than fluticasone propionate for the treatment of allergic rhinitis in children. Allergy. 2016;71(8):1219–1222. doi:10.1111/all.12903
   PubMed Web of Science ®Google Scholar
• Berger W, Sher E, Gawchik S, Fineman S. Safety of a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in children: a randomized clinical trial William Berger, Ellen Sher, Sandra Gawchik, and Stanley Fineman. Allergy Asthma Proc. 2018;39(110):–. doi:10.2500/aap.2018.39.4116
   Google Scholar
• Price D, Shah S, Bhatia S, et al. A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis. J Investig Allergol Clin Immunol. 2013;23(7):495–503.
   PubMed Web of Science ®Google Scholar
• Klimek L, Bachert C, Stjärne P, et al. MP-AzeFlu provides rapid and effective allergic rhinitis control in real life: a pan-European study. Allergy Asthma Proc. 2016;37(5):376–386. doi:10.2500/aap.2016.37.3979
   PubMed Web of Science ®Google Scholar
• Klimek L, Bachert C, Mosges R, et al. Effectiveness of MP29-02 for the treatment of allergic rhinitis in real-life: results from a noninterventional study. Allergy Asthma Proc. 2015;36(1):40–47. doi:10.2500/aap.2015.36.3823
   PubMed Web of Science ®Google Scholar
• Stjarne P, Strand V, Theman K, Ehnhage A. Control of allergic rhinitis with MP-AzeFlu: a noninterventional study of a Swedish cohort. Rhinology. 2019;57(4):279–286. doi:10.4193/Rhin18.028
   PubMed Web of Science ®Google Scholar
• Agache I, Doros IC, Leru PM, Bucur I, Poenaru M, Sarafoleanu C. MP-AzeFlu provides rapid and effective allergic rhinitis control: results of a non-interventional study in Romania. Rhinology. 2018;56(1):33. doi:10.4193/Rhin16.278
   PubMed Web of Science ®Google Scholar
• Scadding G, Price D, El-Shanawany T, et al. Multicentre, non-interventional study to assess the profile of patients with uncontrolled rhinitis prescribed a novel formulation of azelastine hydrochloride and fluticasone propionate in a single spray in routine clinical practice in the UK. BMJ Open. 2017;7(4):e014777. doi:10.1136/bmjopen-2016-014777
   PubMed Web of Science ®Google Scholar
• Haahr PA, Jacobsen C, Christensen ME. MP‐AzeFlu provides rapid and effective allergic rhinitis control: results of a non‐interventional study in Denmark. Int Forum Allergy Rhinol. 2019;9(4):388–395. doi:10.1002/alr.22258
   PubMed Web of Science ®Google Scholar
• Dollner R, Larsen PL, Dheyauldeen S, Steinsvåg S. A multicenter, prospective, noninterventional study in a Norwegian cohort of patients with moderate-to-severe allergic rhinitis treated with MP-AzeFlu. Allergy Rhinol. 2017;8(3):e148–e156. doi:10.2500/ar.2017.8.0216
   PubMedGoogle Scholar
• Ekstedt S, Kumlien Georén S, Cardell LO. Effects of MP-AzeFlu enhanced by activation of bitter taste receptor TAS2R. Allergy Asthma Clin Immunol. 2020;16(1):1–4. doi:10.1186/s13223-020-00438-w
   PubMed Web of Science ®Google Scholar
• Roca-Ferrer J, Pujols L, Pérez-González M, et al. Superior effect of MP-AzeFlu than azelastine or fluticasone propionate alone on reducing inflammatory markers. Allergy Asthma Clin Immunol. 2018;14(1):86. doi:10.1186/s13223-018-0311-4
   PubMedGoogle Scholar
• Berger WE, Bachert C, Allara R, et al. Evaluation of in vitro penetration of fluticasone propionate from MP-azeflu and fluticasone propionate nasal spray through epiairway™ 606 tissues using vertical diffusion cells. J Asth Aller. 2020;13:187–192. doi:10.2147/JAA.S238421
   PubMed Web of Science ®Google Scholar
• Meltzer EO, Bachert C, Kopietz F, Koltun A, Maus J, D’Addio AD Deposition characteristics of a novel intranasal formulation of azelastine hydrochloride plus fluticasone propionate in an anatomic model of the human nasal cavity. InAllergy and Asthma Proceedings; 2020.
   Google Scholar
• Bousquet J, Meltzer E, Couroux P, et al. Onset of action of the fixed combination intranasal azelastine-fluticasone propionate in an allergen exposure chamber. J Allergy Clin Immunol Pract. 2018;6(5):1726–1732. doi:10.1016/j.jaip.2018.01.031
   PubMed Web of Science ®Google Scholar
• Fairshter RD, Novey HS, Marchioli LE, Wilson AF. Large airway constriction in allergic rhinitis: response to inhalation of helium-oxygen. J Allergy Clin Immunol. 1979;63(1):139–146. doi:10.1016/0091-6749(79)90160-X
   Web of Science ®Google Scholar
• Rossi O, Massaro I, Caminati M, Quecchia C, Fassio F. Escaping the trap of allergic rhinitis. Clini Molec Aller. 2015;13(1):1–5. doi:10.1186/s12948-015-0023-y
   PubMedGoogle Scholar
• Kaulsay R, Nguyen DT, Kuhl HC. Real‐life effectiveness of MP‐AzeFlu in Irish patients with persistent allergic rhinitis, assessed by visual analogue scale and endoscopy. Immun Inflamm Dis. 2018;6(4):456–464. doi:10.1002/iid3.237
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Dymista prescribing information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202236s000lbl.pdf. Accessed 14 September 2020.
   Google Scholar
• Price D, Klimek L, Gálffy G, et al. Allergic rhinitis and asthma symptoms in a real-life study of MP-AzeFlu to treat multimorbid allergic rhinitis and asthma. Clini Molec Aller. 2020;18(1):1. doi:10.1186/s12948-020-00130-9
   PubMedGoogle Scholar
• De Jong HJI, Voorham J, Scadding GK, et al. Evaluating the real-life effect of MP-AzeFlu on asthma outcomes in patients with allergic rhinitis and asthma in UK primary care. World Allergy Organ J. 2020;13(12):100490. doi:10.1016/j.waojou.2020.100490
   PubMed Web of Science ®Google Scholar
• Klimek L, Poletti SC, Sperl A, et al. Olfaction in patients with allergic rhinitis: an indicator of successful MP‐AzeFlu therapy. Int Forum Aller Rhinol. 2017;7(3):287–292. doi:10.1002/alr.21877
   PubMed Web of Science ®Google Scholar
• Feijen J, Seys SF, Steelant B, et al. Prevalence and triggers of self-reported nasal hyperreactivity in adults with asthma. World Allergy Organ J. 2020;13(6):100–132. doi:10.1016/j.waojou.2020.100132
   Web of Science ®Google Scholar
• Prapamontol T, Norbäck D, Thongjan N, et al. Asthma and rhinitis in wet and dry season among students in upper northern Thailand: the role of building dampness and household air pollution. Int J Environ Health Res. 2022;1–13. doi:10.1080/09603123.2022.2047902
   Web of Science ®Google Scholar
• Narita D, Oanh N, Sato K. Pollution characteristics and policy actions on fine particulate matter in a growing asian economy: the case of Bangkok metropolitan region. Atmosphere. 2019;10(5):227. doi:10.3390/atmos10050227
   Web of Science ®Google Scholar
• Kortekaas Krohn I, Callebaut I, Alpizar YA, et al. MP29-02 reduces nasal hyperreactivity and nasal mediators in patients with house dust mite-allergic rhinitis. Allergy. 2018;73(5):1084–1093. doi:10.1111/all.13349
   PubMed Web of Science ®Google Scholar
• Klimek L, Bachert C, Pfaar O, et al. ARIA guideline 2019: treatment of allergic rhinitis in the German health system. Allergo J Int. 2019;28(7):255–276. doi:10.1007/s40629-019-00110-9
   Google Scholar
• Aneeza WH, Husain S, Rahman RA, et al. Efficacy of mometasone furoate and fluticasone furoate on persistent allergic rhinoconjunctivitis. Allergy Rhinol. 2013;4(3):e120–6. doi:10.2500/ar.2013.4.0065
   PubMedGoogle Scholar
• Salapatek AM, Lee J, Patel D, et al. Solubilized nasal steroid (CDX-947) when combined in the same solution nasal spray with an antihistamine (CDX-313) provides improved, fast-acting symptom relief in patients with allergic rhinitis. Allergy Asthma Proc. 2011;32(3):221–229. doi:10.2500/aap.2011.32.3444
   PubMed Web of Science ®Google Scholar
• Patel P, D’Andrea C, Sacks HJ. Onset of action of azelastine nasal spray compared with mometasone nasal spray and placebo in subjects with seasonal allergic rhinitis evaluated in an environmental exposure chamber. Am J Rhinol. 2007;21(4):499–503. doi:10.2500/ajr.2007.21.3058
   PubMedGoogle Scholar
• Shah SR, Nayak A, Ratner P, Roland P, Michael Wall G. Effects of olopatadine hydrochloride nasal spray 0.6% in the treatment of seasonal allergic rhinitis: a Phase III, multicenter, randomized, double-blind, active- and placebo-controlled study in adolescents and adults. Clin Ther. 2009;31(1):99–107. doi:10.1016/j.clinthera.2009.01.016
   PubMed Web of Science ®Google Scholar
• Ellis AK, Zhu Y, Steacy LM, Walker T, Day JH. A four-way, double-blind, randomized, placebo controlled study to determine the efficacy and speed of azelastine nasal spray, versus loratadine, and cetirizine in adult subjects with allergen-induced seasonal allergic rhinitis. Allergy Asthma Clin Immunol. 2013;9(1):16. doi:10.1186/1710-1492-9-16
   PubMed Web of Science ®Google Scholar
• Day JH, Briscoe MP, Rafeiro E, Hewlett D, Chapman D, Kramer B. Randomized double-blind comparison of cetirizine and fexofenadine after pollen challenge in the environmental exposure unit: duration of effect in subjects with seasonal allergic rhinitis. Allergy Asthma Proc. 2004;25(1):59–68.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Schünemann HJ, Togias A, et al. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020;145(1):70–80. doi:10.1016/j.jaci.2019.06.049
   PubMed Web of Science ®Google Scholar
• Greisner III WA. Onset of action for the relief of allergic rhinitis symptoms with second-generation antihistamines. In Allergy and asthma proceedings. 2004;25(2):81.
   PubMed Web of Science ®Google Scholar
• Sur DK, Scandale S. Treatment of allergic rhinitis. American family physician. 2010;81(12):1440–6.
   PubMed Web of Science ®Google Scholar
• Recto MT, Gabriel MT, Kulthanan K, Tantilipikorn P. Selecting optimal second-generation antihistamines for allergic rhinitis and urticaria in Asia. Clini Molec Aller. 2017;15(1):19. doi:10.1186/s12948-017-0074-3
   PubMedGoogle Scholar
• Hellings PW, Dobbels F, Denhaerynck K, Piessens M, Ceuppens JL, De Geest S. Explorative study on patient’s perceived knowledge level, expectations, preferences and fear of side effects for treatment for allergic rhinitis. Clin Transl Allergy. 2012;1(1):9. doi:10.1186/2045-7022-2-9
   Google Scholar
• Wise SK, Lin SY, Toskala E. International consensus statement on allergy and rhinology: allergic rhinitis—executive summary. Int Forum Allergy Rhinol. 2018;8(2):85–107. doi:10.1002/alr.22070
   PubMed Web of Science ®Google Scholar